U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest ...

In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical ...

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $928 from $973 and keeps a Buy rating on the shares. The firm is updating its ...